Methods to evaluate the impact of SARS-CoV-2 nucleocapsid mutations on antigen detection by rapid diagnostic tests

Mutations in the nucleocapsid of SARS-CoV-2 may interfere with antigen detection by diagnostic tests. We used several methods to evaluate the effect of various SARS-CoV-2 nucleocapsid mutations on the performance of the Panbio™ and BinaxNOW™ lateral flow rapid antigen tests and a prototype high-thro...

Full description

Bibliographic Details
Main Authors: Bryan C Tieman, Stephen Kovacs, Mary A Rodgers, Aurash Mohaimani, Svetoslava Gregory, David Christensen, Jeffrey A Moore, Lici Schurig-Briccio, James Hartnett, Alak Kar, Aaron Leeman, Angel Palmer, Lauren Rogers, Brian Dragoo, Steven Muszynski, Deborah Noblesmith, Samantha Gardner, Abigail Snipe-Bushey, Anna Kill, Xinxin Luo, Sneha Cherukuri, Tracey Rae, Christopher C Marohnic, Gavin A Cloherty, Anthony Scott Muerhoff, Philip M Hemken
Format: Article
Language:English
Published: Future Science Ltd 2022-09-01
Series:BioTechniques
Subjects:
Online Access:https://www.future-science.com/doi/10.2144/btn-2022-0020
Description
Summary:Mutations in the nucleocapsid of SARS-CoV-2 may interfere with antigen detection by diagnostic tests. We used several methods to evaluate the effect of various SARS-CoV-2 nucleocapsid mutations on the performance of the Panbio™ and BinaxNOW™ lateral flow rapid antigen tests and a prototype high-throughput immunoassay that utilizes Panbio antibodies. Variant detection was also evaluated by immunoblot and BIAcore™ assay. A panel of 23 recombinant nucleocapsid antigens (rAgs) were produced that included mutations found in circulating SARS-CoV-2 variants, including variants of concern. All mutant rAgs were detected by all assays, at a sensitivity equivalent to wild-type control (Wuhan strain). Thus, using a rAg approach, we found that the SARS-CoV-2 nucleocapsid mutations examined do not directly impact antigen detection or antigen assay performance.
ISSN:0736-6205
1940-9818